Putting Patients First Blog
JUNE 26, 2025
The NHC supports the efforts to reduce out-of-pocket costs for Medicare beneficiaries and appreciates CMS’ work to establish a process that seeks to incorporate patient perspectives into drug pricing policy. This will allow other stakeholders (e.g.,
Pharmaceutical Technology
JUNE 9, 2025
For example, Recordati’s Cystadane (betaine) was centrally approved in 2007 but did not see its first reimbursement in Poland until 2023. In Romania, Novartis’s Atriance (nelarabine) was also centrally approved in 2007 but did not receive its first reimbursement in Romania until 2021.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JULY 29, 2021
Advanz hiked the price of a pack of liothyronine tablets – used to treat thyroid hormone deficiency – from £20 in 2009 to £248 in 2017, taking advantage of a lack of competition for the drug even though it was out of patent. The post UK fines Advanz £100m for raising thyroid drug price tenfold appeared first on.
pharmaphorum
AUGUST 20, 2020
illegally paid Medicare co-payment costs through purportedly independent charities while at the same time jacking up the price of Copaxone, which had no generic rival at the time. The US government alleges that the payments occurred from 2007 until the end of 2015, to charities called The Assistance Fund (TAF) and Chronic Disease Fund (CDF).
pharmaphorum
SEPTEMBER 24, 2020
Gilead has paid $97 million to resolve claims by US authorities that it acted illegally by using a charitable foundation as a conduit to fund co-payments of thousands of Medicare patients taking its pulmonary arterial hypertension drug, Letairis.
Putting Patients First Blog
SEPTEMBER 7, 2023
The Duchenne Registry began in 2007, when a group of thought leaders in the Duchenne muscular dystrophy community began discussing the need for a new kind of resource that would connect and serve the needs of the entire community. The average age at loss of ambulation for registrants who never used corticosteroids was 10.5
European Pharmaceutical Review
SEPTEMBER 14, 2023
Market uncertainty Rising operational costs, stiffening competition, ongoing patent expirations, evolving environmental and social governance requirements and increasing pressure on drug prices mean the industry will have to navigate thoughtfully to be successful amid this complicated mix of financial and strategic risks.
Expert insights. Personalized for you.
52 
Let's personalize your content